Journal ArticleDOI
Glucose Analog Inhibitors of Glycogen Phosphorylases as Potential Antidiabetic Agents: Recent Developments
TLDR
Recent developments in the synthesis and evaluation of glucopyranosylidene-spiro-thiohydantoin 18 and further anomerically bifunctional glucose derivatives which may be good inhibitors of GP are surveyed.Abstract:
Diabetes is among the largest contributors to global mortality through its long term complications. The worldwide epidemic of type 2 diabetes has been stimulating the quest for new concepts and targets for the treatment of this incurable disease. A new target is glycogen phosphorylase (GP), the main regulatory enzyme in the liver responsible for the control of blood glucose levels. One of several approaches to influence the action of GP is the use of glucose derivatives as active site inhibitors. This field of research commenced 10-15 years ago and, due to joint efforts in computer aided molecular design, organic synthesis, protein crystallography, and biological assays, resulted in glucopyranosylidene-spiro-hydantoin 16 (Ki = 3-4 μM) as the most efficient glucose analog inhibitor of GP of that time. The present paper surveys the recent developments of this field achieved mainly in the last five years: the synthesis and evaluation of glucopyranosylidene-spiro-thiohydantoin 18 (Ki = 5 μM) which has proven equipotent with 16, and is available in gram amounts; furanosylidene- and xylopyranosylidene-spiro-(thio)hydantoins whose ineffectiveness (Ki > 10 μM) confirmed the high specificity of the catalytic site of GP towards the D-glucopyranosyl unit; “open” hydantoins like methyl N-(1-carboxamido-D-glucopyranosyl)carbamate 37 (Ki = 16 > M) and N-acyl-N-(β-Dglucopyranosyl) ureas among them the to date best glucose analog inhibitor N-(2-naphthoyl)-N-(β-D-glucopyranosyl)urea (35, Ki = 0.4 μM) which can also bind to the so-called new allosteric site of GP; C-(β-D-glucopyranosyl)heterocycles (tetrazole, 1,3,4-oxadiazoles, benzimidazole (Ki = 11 μM), and benzothiazole). Iminosugars like isofagomine (45, IC50 = 0.7 μM), noeuromycin (53, IC50 = 4 μM), and azafagomine (54, IC50 = 13.5 μM) also bind strongly to the active site of GP, however, substitution on the nitrogens makes the binding weaker. The natural product five-membered iminosugar DAB (56) exhibited IC50 ∼ 0.4-0.5 μM. Azoloperhydropyridines which can be regarded iminosugar-annelated heterocycles show moderate inhibition of GP: nojiritetrazole 12 (Ki = 53 μM) is the best inhibitor and fewer nitrogens in the five-membered ring weakens the binding. Physiological investigations have been carried out with N-acetyl-β-Dglucopyranosylamine 6, spiro-thiohydantoin 18, isofagomine 45, and DAB 56 to underline the potential use of these compounds in the treatment of type 2 diabetes. Computational methods suggest to synthesize further anomerically bifunctional glucose derivatives which may be good inhibitors of GP.read more
Citations
More filters
Journal ArticleDOI
Fluorine in medicinal chemistry: Recent therapeutic applications of fluorinated small molecules
TL;DR: Fluorinated drugs for treatment of diseases of the central nervous system, various cardiovascular diseases and obesity, antibacterial agents, and antifungal therapy are reviewed.
Journal ArticleDOI
The Polar Hydrophobicity of Fluorinated Compounds
TL;DR: Improved oral bioavailability is seen in some systems where fluorine substitution leads to improved hydrolytic stability and mechanism-based inhibitors for a wide variety of diseases and to chemotherapeutic drugs.
Journal ArticleDOI
Glycogen metabolism has a key role in the cancer microenvironment and provides new targets for cancer therapy
TL;DR: An overview of glycogen metabolism and its regulation is provided, with a focus on its role in metabolic reprogramming of cancer cells under stress conditions such as hypoxia, glucose deprivation and anticancer treatment.
Journal ArticleDOI
Tactics and strategies for the synthesis of iminosugar C-glycosides: a review
TL;DR: The purpose of this review is to provide an overview of the versatile strategies that have been developed to synthesize this family of stable imino-analogues of glycosides and glycoconjugates.
Journal ArticleDOI
Crataegus pinnatifida: Chemical Constituents, Pharmacology, and Potential Applications
TL;DR: It has been found that constituents and extracts of C. pinnatifida have broad pharmacological effects with low toxicity on, for example, the cardiovascular, digestive, and endocrine systems, and pathogenic microorganisms, supporting the view that C.pinnatIFida has favorable therapeutic effects.